Individual adaptive dosing of topotecan in ovarian cancer

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 394-399

  Montazeri, Ashraf ^a,b,c,d,e,f   Culine, Stéphane ^a,b,c,d,e,f   Laguerre, Brigitte ^a,b,c,d,e,f   Pinguet, Frédéric ^a,b,c,d,e,f   Lokiec, François ^a,b,c,d,e,f   Albin, Nicolas ^a,b,c,d,e,f   Goupil, Alain ^a,b,c,d,e,f   Déporte Féty, Régine ^a,b,c,d,e,f   Bugat, Roland ^a,b,c,d,e,f   Canal, Pierre ^a,b,c,d,e,f   Chatelut, Etienne ^a,b,c,d,e,f  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CENTRE VAL D AURELLE   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f CLINIQUE PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLATINUM; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEUTROPHILS; OVARIAN NEOPLASMS; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0036187723     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. An overview of the clinical pharmacology of topotecan
2. Clinical pharmacokinetics of topotecan
3. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan
4. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
5. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
6. Phase I and pharmacologic study of topotecan in patients with impaired renal function
7. Population pharmacokinetic model for topotecan derived from phase I clinical trials
8. Phase 1 and pharmacologic studies of topotecan in patients with impaired hepatic function
9. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
10. Topotecan: What dose, what schedule, what route?
11. Camptothecin analogues: Topotecan and irinotecan
12. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours
13. Prediction of creatinine clearance from serum creatinine
14. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma
15. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion
16. Population pharmacokinetics of topotecan: Intraindividual variability of total drug
17. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
18. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
19. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study